## Regional Chapter Annual Report - 2015

<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Rasim Köşelerli, MD, Social Security Institution General Directorate of Universal Health Insurance Department Head, <a href="mailto:rkoselerli@gmail.com">rkoselerli@gmail.com</a></td>
</tr>
<tr>
<td>President-Elect</td>
<td>Zafer Caliskan, Associated Professor, Hacettepe University, Department of Economics, <a href="mailto:caliskan@hacettepe.edu.tr">caliskan@hacettepe.edu.tr</a></td>
</tr>
<tr>
<td>Past President</td>
<td>Hakan Ergun, Professor in Pharmacology, Ankara University, Department of Clinical Pharmacology, <a href="mailto:hakan.ergun@medicine.ankara.edu.tr">hakan.ergun@medicine.ankara.edu.tr</a></td>
</tr>
<tr>
<td>Secretary</td>
<td>Gamze Kuzucu Gurses, Corporate Affairs &amp; Market Access Director, Lundbeck Turkey, <a href="mailto:gurs@lundbeck.com">gurs@lundbeck.com</a></td>
</tr>
<tr>
<td>Treasurer</td>
<td>Kadir Gürsoy, Expert at Social Security Institution General Directorate of Universal Health Insurance, <a href="mailto:kadir_gursoy@hotmail.com">kadir_gursoy@hotmail.com</a></td>
</tr>
<tr>
<td>Director</td>
<td>Ümit Dereli, MD, General Secretary, Association of Research Based Pharmaceutical Companies, <a href="mailto:umit.dereli@aifd.org.tr">umit.dereli@aifd.org.tr</a></td>
</tr>
<tr>
<td>Director</td>
<td>Halil Tunç Köksal, Pharm, Deputy General Secretary, Pharmaceutical Manufacturers Association of Turkey, <a href="mailto:tunc.koksal@ieis.org.tr">tunc.koksal@ieis.org.tr</a></td>
</tr>
<tr>
<td>Director</td>
<td>Sami Türkoğlu, MD, Pharmaceutical Industry Association of Turkey, <a href="mailto:sami.turkoglu@nobel.com.tr">sami.turkoglu@nobel.com.tr</a></td>
</tr>
<tr>
<td>Director</td>
<td>Yalçın Kaya, MD, Market Access Senior Manager, Bristol-Myers Squibb Turkey, <a href="mailto:yalcinkaya@bms.com">yalcinkaya@bms.com</a></td>
</tr>
<tr>
<td>Director</td>
<td>Mete Saylan, MD, Market Access Director, MSD Turkey, <a href="mailto:mete.saylan@merck.com">mete.saylan@merck.com</a></td>
</tr>
<tr>
<td>Director</td>
<td>Cetin Deger, MD, Freelance Consultant, <a href="mailto:cetin.deger@gmail.com">cetin.deger@gmail.com</a></td>
</tr>
<tr>
<td># Members</td>
<td>144</td>
</tr>
</tbody>
</table>

### Describe your Chapter’s accomplishments for 2015 with regard to Scientific and Educational activities.

Discussion meeting on new pricing legislation was conducted. An additional meeting was planned to discuss the alternative reimbursement models, the corresponding legislation and current practice.

### Describe your Chapter’s accomplishments for 2015 with regard to Policy-related activities.

Visits conducted to SSI, MoHealth, MoFinance and MoDevelopment to ensure collaboration and government support in future activities of the ISPOR Turkish SCP Chapter.
Regional Chapter Annual Report - 2015

Describe your Chapter's accomplishments for 2015 with regard to Chapter meetings or conferences.

Three Executive Committee meetings were held in the second half of 2015. Meetings were held regularly every month starting as of October 2015. ISPOR 18th Annual European Congress was attended and a Chapter meeting was organized on 8th November with the attendance of 36 members. The main agenda item was the annual plan for the coming years. The executive committee decided to choose two workshop topics for the next year, namely pricing and alternative reimbursement models. The attendees provided feedback on the workshop topics, methods and KPIs. Applicability of QALY as an outcome measure in reimbursement decisions and role of patient advocacy groups in HTA are suggested as additional topics for the coming years.

Describe your Chapter's accomplishments for 2015 with regard to membership engagement.

New members attracted to join the ISPOR Turkish Chapter with support of the industry associations and our member number has increased from 64 to 144. ISPOR Turkish SCP Chapter closed LinkedIn group was formed to encourage the discussion on relevant topics. Action taken to establish working groups for the organization of the planned workshops and update of the terminology glossary.

Is your Chapter affiliated with any institutions, universities, government or associations (other than ISPOR)? If yes, please list and describe the nature of these affiliations(s).

Yes

Joint Constitution - Society of Clinical Pharmacology

Turkish Society of Clinical Pharmacology

Does your Chapter collect membership dues or fees from individuals for local Chapter membership? If yes, how much are the dues?

No

How many ISPOR International members (paying dues to ISPOR Headquarters) does your Chapter have? Provide an estimate if you do not have an exact count.

100

Does your Chapter have any agreements or sponsorship arrangements with any for-profit companies, governments, health authorities or associations? If yes, please describe.

No

Does your Chapter employ paid administrative or management staff (Association Management Company, contracted staff)?

No

Other than the page for your Chapter on the ISPOR website, does your Chapter maintain a website?

No
When did your Chapter last update the ISPOR Chapter Constitution? In the last 3 years.

Has your Chapter (as a group, not as individual members) submitted formal comments or responses to any government or health authority in 2014 or 2015? If yes, what was the topic or issue? No

Does your Chapter (as a group, not as individual members) interact in some way with the HTA or other official guidelines in your country? If yes, please name guideline(s) and describe. No

Does your Chapter have any committees or special interest groups? Please indicate and briefly describe. No

Academia % 15
Government/HTA Agency % 8
Industry % 68
Consulting % 3
Clinicians % 6
Student % 0
Other % 0

Networking and scientific & educational platform to discuss recent developments, collaborative workshops with other ISPOR chapters will be also planned to enable best practice sharing.

What benefits does your Chapter offers to its members? The numbers of members has increased from 64 to 144. Members from the government/HTA agency have been engaged for collaboration. We have a dedicated executive committee meeting regularly to plan new activities.

What are the most significant achievements of your Chapter in 2015? Having no budget allocated for chapter activities.
How does your Chapter fulfill ISPOR’s mission to promote health economics and outcomes research excellence to improve decision making for health globally? Describe how it supports the development and promotion of the discipline of health economics and outcomes research in your region.

How can the ISPOR organization as a whole (Staff, Board, Consortia, Networks, etc.) better support your Chapter?

Please indicate who prepared this report, include title, phone, email.

Our chapter has planned 2016 activities to fulfill this mission: Collaborative workshops with other ISPOR chapters are to be planned for the second half of 2016. The potential topics will be discussed at the executive committee meeting for future proposals. Terminology working group will start to work on the basic glossary and then the HEOR terminology book will be updated accordingly throughout the year. Pricing workshop will be organized to discuss the legislative changes and current practice. The objective will be defining the ideal pricing system. Collaboration with the Social Security Institution and Academia is planned to retrieve and analyze Turkish incidence and prevalence data of major diseases. Workshop on alternative reimbursement models will be conducted to discuss the current practice, risks and opportunities.

Speaker support can be provided for the planned workshops and symposia. Istanbul can be assessed as candidate venue for ISPOR Annual European Congress in 2018.

Gamze Kuzucu Gurses, Secretary of ISPOR Turkish SCP Chapter, 00905334755439, gurs@lundbeck.com